Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2010

01-12-2010 | Research Article

Evaluation of three brands of drug interaction software for use in intensive care units

Authors: Adriano Max Moreira Reis, Silvia Helena De Bortoli Cassiani

Published in: International Journal of Clinical Pharmacy | Issue 6/2010

Login to get access

Abstract

Objective To evaluate drug interaction software programs and determine their accuracy in identifying drug-drug interactions that may occur in intensive care units. Setting The study was developed in Brazil. Method Drug interaction software programs were identified through a bibliographic search in PUBMED and in LILACS (database related to the health sciences published in Latin American and Caribbean countries). The programs’ sensitivity, specificity, and positive and negative predictive values were determined to assess their accuracy in detecting drug–drug interactions. The accuracy of the software programs identified was determined using 100 clinically important interactions and 100 clinically unimportant ones. Stockley’s Drug Interactions 8th edition was employed as the gold standard in the identification of drug-drug interaction. Main outcome Sensitivity, specificity, positive and negative predictive values. Results The programs studied were: Drug Interaction Checker (DIC), Drug-Reax (DR), and Lexi-Interact (LI). DR displayed the highest sensitivity (0.88) and DIC showed the lowest (0.69). A close similarity was observed among the programs regarding specificity (0.88–0.92) and positive predictive values (0.88–0.89). The DIC had the lowest negative predictive value (0.75) and DR the highest (0.91). Conclusion The DR and LI programs displayed appropriate sensitivity and specificity for identifying drug–drug interactions of interest in intensive care units. Drug interaction software programs help pharmacists and health care teams in the prevention and recognition of drug–drug interactions and optimize safety and quality of care delivered in intensive care units.
Literature
1.
go back to reference Mouly S, Meune C, Bergmann JF. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. Intensive Care Med. 2009;35(3):417–29.CrossRefPubMed Mouly S, Meune C, Bergmann JF. Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. Intensive Care Med. 2009;35(3):417–29.CrossRefPubMed
2.
go back to reference Spriet I, Meersseman W, de Hoon J, et al. Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. 2009;35(4):603–12.CrossRefPubMed Spriet I, Meersseman W, de Hoon J, et al. Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med. 2009;35(4):603–12.CrossRefPubMed
3.
go back to reference Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380–5.PubMed Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380–5.PubMed
4.
go back to reference Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm. 1999;56(15):1524–9.PubMed Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm. 1999;56(15):1524–9.PubMed
5.
go back to reference Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE. Armstrong E. Evaluation of the performance of drug–drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006;12(5):383–9.PubMed Abarca J, Colon LR, Wang VS, Malone DC, Murphy JE. Armstrong E. Evaluation of the performance of drug–drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm. 2006;12(5):383–9.PubMed
6.
go back to reference Dallenbach MF, Bovier PA, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM. 2007;100(11):691–7.CrossRefPubMed Dallenbach MF, Bovier PA, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM. 2007;100(11):691–7.CrossRefPubMed
7.
go back to reference Clauson KA, Polen HH, Marsh WA. Clinical decision support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy. 2007;27(12):1651–8.CrossRefPubMed Clauson KA, Polen HH, Marsh WA. Clinical decision support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy. 2007;27(12):1651–8.CrossRefPubMed
8.
go back to reference Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug–drug interaction software for personal digital assistants. Ann Pharmacother. 2006;40(5):850–5.CrossRefPubMed Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug–drug interaction software for personal digital assistants. Ann Pharmacother. 2006;40(5):850–5.CrossRefPubMed
9.
go back to reference Lam MV, McCart MG, Tsourounis C. An assessment of free, online drug–drug interaction screening programs (DSPs). Hosp Pharm. 2003;38(7):662–8. Lam MV, McCart MG, Tsourounis C. An assessment of free, online drug–drug interaction screening programs (DSPs). Hosp Pharm. 2003;38(7):662–8.
10.
go back to reference Pham PA. Drug–drug interaction programs in clinical practice. Clin Pharmacol Ther. 2008;83(3):396–8.CrossRefPubMed Pham PA. Drug–drug interaction programs in clinical practice. Clin Pharmacol Ther. 2008;83(3):396–8.CrossRefPubMed
11.
go back to reference Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30(4):367–74.CrossRefPubMed Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30(4):367–74.CrossRefPubMed
12.
go back to reference Baxter K (Ed). Stockley’s drug interactions. 8th ed. London: Pharmaceutical Press; 2008. ISBN 978-0-85369-755-8. Baxter K (Ed). Stockley’s drug interactions. 8th ed. London: Pharmaceutical Press; 2008. ISBN 978-0-85369-755-8.
13.
go back to reference Romac DR, Albertson TE. Drug interactions in the intensive care unit. Clin Chest Med. 1999;20(2):385–99.CrossRefPubMed Romac DR, Albertson TE. Drug interactions in the intensive care unit. Clin Chest Med. 1999;20(2):385–99.CrossRefPubMed
14.
go back to reference Mann HJ, Wittbrodt ET. Identifying drug usage patterns in the intensive care unit. Pharmacoeconomics. 1993;4(4):235–9.CrossRefPubMed Mann HJ, Wittbrodt ET. Identifying drug usage patterns in the intensive care unit. Pharmacoeconomics. 1993;4(4):235–9.CrossRefPubMed
15.
go back to reference Mann HJ. Drug-associated disease: cytocrome P450 interactions. Crit Care Clin. 2006;22(2):329–45.CrossRefPubMed Mann HJ. Drug-associated disease: cytocrome P450 interactions. Crit Care Clin. 2006;22(2):329–45.CrossRefPubMed
16.
go back to reference Biswal SP, Mishra S, Malhotra, Puri GD, Pandhi P. Drug utilization pattern in the intensive care unit of a tertiary care hospital. J.Clin.Pharmacol. 2006;46(8):945–51.CrossRefPubMed Biswal SP, Mishra S, Malhotra, Puri GD, Pandhi P. Drug utilization pattern in the intensive care unit of a tertiary care hospital. J.Clin.Pharmacol. 2006;46(8):945–51.CrossRefPubMed
17.
go back to reference Hammes JA, Pfuetzenreiter F, Silveira F, Koenig A, Westphal GA. Potential drug interactions prevalence in intensive care units. Rev Bras Terap Intensiva. 2008;20(4):349–54. Hammes JA, Pfuetzenreiter F, Silveira F, Koenig A, Westphal GA. Potential drug interactions prevalence in intensive care units. Rev Bras Terap Intensiva. 2008;20(4):349–54.
18.
go back to reference Bustamante GDD, Cabrera C, Duran GMG, Medina TJN. Detección de interacciones medicamentosas, em pacientes ingresados a la unidad de cuidados intensivos del Instituto Autônomo Hospital Universitário de los Andes. Vitae Academia Biomédica Digita. 2005;25(7):1–16. Bustamante GDD, Cabrera C, Duran GMG, Medina TJN. Detección de interacciones medicamentosas, em pacientes ingresados a la unidad de cuidados intensivos del Instituto Autônomo Hospital Universitário de los Andes. Vitae Academia Biomédica Digita. 2005;25(7):1–16.
19.
go back to reference Gordis L. Epidemiology. 2 ed. Philadelphia: W.B.Saunders Company; 2000. ISBN 0-7216-8338-X. Gordis L. Epidemiology. 2 ed. Philadelphia: W.B.Saunders Company; 2000. ISBN 0-7216-8338-X.
20.
go back to reference Rodríguez-Terol A, Caraballo MO, Palma D, Santos-Ramos B, Molina T, Desongles T, Aguilar A. Quality of interaction database management systems. Farm Hosp. 2009;33(3):134–46.CrossRefPubMed Rodríguez-Terol A, Caraballo MO, Palma D, Santos-Ramos B, Molina T, Desongles T, Aguilar A. Quality of interaction database management systems. Farm Hosp. 2009;33(3):134–46.CrossRefPubMed
27.
go back to reference Ko Y, Abarca J, Malone DC, Dare DC, Geraets D, Houranieh A, Jones WN, Nichol WP, Schepers GP, Wilhardt M. Practitioners’ views on computerized drug-drug interaction alerts in the VA system. J Am Med Inform Assoc. 2007;14(1):56–64.CrossRefPubMed Ko Y, Abarca J, Malone DC, Dare DC, Geraets D, Houranieh A, Jones WN, Nichol WP, Schepers GP, Wilhardt M. Practitioners’ views on computerized drug-drug interaction alerts in the VA system. J Am Med Inform Assoc. 2007;14(1):56–64.CrossRefPubMed
28.
go back to reference Paterno MD, Maviglia SM, Gorman PN, et al. Tiering drug–drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc. 2009;16(1):40–6.CrossRefPubMed Paterno MD, Maviglia SM, Gorman PN, et al. Tiering drug–drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc. 2009;16(1):40–6.CrossRefPubMed
29.
go back to reference Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65(24):2347–57.CrossRefPubMed Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65(24):2347–57.CrossRefPubMed
30.
go back to reference Amariles P, Giraldo NA, Faus MJ. Interacciones medicamentosas : aproximación para estabelecer y evaluar su relevância clínica. Med Clin. 2007;129(1):27–35.CrossRef Amariles P, Giraldo NA, Faus MJ. Interacciones medicamentosas : aproximación para estabelecer y evaluar su relevância clínica. Med Clin. 2007;129(1):27–35.CrossRef
31.
go back to reference Rodríguez Terol A, Santos Ramos B, Caraballo Camacho M, Ollero Baturone M. Relevancia clínica de las interacciones medicamentosas. Med Clin. 2008;130(19):758–9.CrossRef Rodríguez Terol A, Santos Ramos B, Caraballo Camacho M, Ollero Baturone M. Relevancia clínica de las interacciones medicamentosas. Med Clin. 2008;130(19):758–9.CrossRef
Metadata
Title
Evaluation of three brands of drug interaction software for use in intensive care units
Authors
Adriano Max Moreira Reis
Silvia Helena De Bortoli Cassiani
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9445-2

Other articles of this Issue 6/2010

International Journal of Clinical Pharmacy 6/2010 Go to the issue